Open access
Open access
Powered by Google Translator Translator

Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

12 Apr, 2021 | 01:24h | UTC

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial – The Lancet Respiratory Medicine

Commentary: Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 – The Lancet Respiratory Medicine


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.